CA2652958C - Deoxynojirimycin and d-arabinitol analogs and methods of using - Google Patents

Deoxynojirimycin and d-arabinitol analogs and methods of using Download PDF

Info

Publication number
CA2652958C
CA2652958C CA2652958A CA2652958A CA2652958C CA 2652958 C CA2652958 C CA 2652958C CA 2652958 A CA2652958 A CA 2652958A CA 2652958 A CA2652958 A CA 2652958A CA 2652958 C CA2652958 C CA 2652958C
Authority
CA
Canada
Prior art keywords
substituted
groups
compound
unsubstituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2652958A
Other languages
English (en)
French (fr)
Other versions
CA2652958A1 (en
Inventor
Terry D. Butters
Raymond A. Dwek
George W. J. Fleet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of CA2652958A1 publication Critical patent/CA2652958A1/en
Application granted granted Critical
Publication of CA2652958C publication Critical patent/CA2652958C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2652958A 2006-05-24 2007-05-22 Deoxynojirimycin and d-arabinitol analogs and methods of using Expired - Fee Related CA2652958C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80277606P 2006-05-24 2006-05-24
US60/802,776 2006-05-24
PCT/US2007/069448 WO2007140184A2 (en) 2006-05-24 2007-05-22 Deoxynojirimycin and d-arabinitol analogs and methods of using

Publications (2)

Publication Number Publication Date
CA2652958A1 CA2652958A1 (en) 2007-12-06
CA2652958C true CA2652958C (en) 2015-11-17

Family

ID=38779322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2652958A Expired - Fee Related CA2652958C (en) 2006-05-24 2007-05-22 Deoxynojirimycin and d-arabinitol analogs and methods of using

Country Status (8)

Country Link
US (1) US8975280B2 (US07794700-20100914-C00152.png)
EP (1) EP2023927B1 (US07794700-20100914-C00152.png)
JP (2) JP5241709B2 (US07794700-20100914-C00152.png)
CN (2) CN104876855A (US07794700-20100914-C00152.png)
CA (1) CA2652958C (US07794700-20100914-C00152.png)
ES (1) ES2537572T3 (US07794700-20100914-C00152.png)
HK (1) HK1214261A1 (US07794700-20100914-C00152.png)
WO (1) WO2007140184A2 (US07794700-20100914-C00152.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088581A2 (en) * 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
ES2579628T3 (es) 2009-02-23 2016-08-12 Emergent Virology Llc Iminoazúcares y métodos de tratamiento de enfermedades virales
JP5951996B2 (ja) * 2009-02-24 2016-07-13 ユナイテッド セラピューティクス コーポレーション イミノ糖及びアレナウイルス感染症を治療する方法
JP2012521981A (ja) * 2009-03-27 2012-09-20 ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード コレステロールレベル低下リポソーム
US20100248365A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
JP5634510B2 (ja) * 2009-06-12 2014-12-03 ユナイテッド セラピューティクス コーポレイション イミノ糖ならびにブニヤウイルスおよびトガウイルス疾患を治療する方法
CN102625796B (zh) * 2009-09-04 2015-03-11 联合治疗公司 治疗正粘病毒感染的方法
ES2527623T3 (es) * 2009-09-04 2015-01-27 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus
WO2011028781A1 (en) * 2009-09-04 2011-03-10 United Therapeutics Corporation Methods of treating poxviral infections
JP2015518896A (ja) 2012-06-06 2015-07-06 ユニザー ヴィロロジー，エルエルシー 新規イミノ糖およびそれらの用途
CA2906675A1 (en) * 2013-03-15 2014-09-18 Unither Virology, Llc Antibacterial compounds
CN106102464A (zh) * 2013-05-02 2016-11-09 牛津大学之校长及学者 采用亚氨基糖的糖脂抑制
KR20160055916A (ko) 2013-09-16 2016-05-18 이머전트 바이롤로지 엘엘씨 데옥시노지리마이신 유도체 및 그의 이용 방법
SG10201903630UA (en) * 2014-11-05 2019-05-30 Emergent Virology Llc Iminosugars useful for the treatment of viral diseases
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS54106477A (en) 1978-02-03 1979-08-21 Nippon Shinyaku Co Ltd Moranoline derivative
JPS5943948B2 (ja) * 1978-07-06 1984-10-25 日本新薬株式会社 置換モラノリン誘導体
JPS5943949B2 (ja) 1978-09-29 1984-10-25 日本新薬株式会社 モラノリンのｎ−置換誘導体
JPS5943947B2 (ja) * 1978-05-03 1984-10-25 日本新薬株式会社 Ｎ−置換モラノリン誘導体
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
DE3007078A1 (de) 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
DE3024901A1 (de) 1980-07-01 1982-01-28 Bayer Ag, 5090 Leverkusen Herbizide mittel auf basis von piperidin-derivaten
DE3620645A1 (de) 1985-12-20 1987-07-02 Bayer Ag 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung
JPS62155291A (ja) 1985-12-20 1987-07-10 バイエル・アクチエンゲゼルシヤフト ３−アミノ−４，５−ジヒドロキシピペリジン類、それらの製造方法及びそれらの使用
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
JPH0643306B2 (ja) * 1988-02-12 1994-06-08 明治製菓株式会社 癌細胞転移抑制剤
EP0350012A3 (en) * 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
DE68925940T2 (de) * 1988-11-03 1996-10-24 Searle & Co Dideoxy-L-arabinitol Derivate als Antivirus-Verbindungen
US5256788A (en) 1989-02-13 1993-10-26 Nippon Shinyaku Co. Ltd. Moranoline derivatives and their production and the use of moranoline and its derivatives as a stabilizing agent for enzymes
JPH0675510B2 (ja) 1989-02-13 1994-09-28 日本新薬株式会社 モラノリン誘導体の製法
US5051401A (en) * 1989-04-07 1991-09-24 University Of South Alabama Inhibition of mineral deposition by phosphorylated and related polyanionic peptides
DE4009561A1 (de) 1990-03-24 1991-09-26 Bayer Ag Neue desoxynojirimycinderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
WO1992000277A1 (fr) 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US5290948A (en) 1990-09-17 1994-03-01 Mcneilab, Inc. Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
DK0739205T3 (da) 1994-01-13 2000-05-01 Searle & Co Anvendelse af N-alkylderivater af 1,5-didesoxy-1,5-imino-D-glucitol til behandling af hepatitis-B-virusinfektioner
WO1995022975A1 (en) 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
MY122499A (en) * 1997-11-10 2006-04-29 Searle & Co Use of alkylated iminosugars to treat multidrug resistance
BR9907882A (pt) 1998-02-12 2000-10-17 Searle & Co Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
CN1422156A (zh) 2000-02-14 2003-06-04 法马西亚公司 N－取代的－1,5－二脱氧－1,5－亚氨基－d－葡萄糖醇化合物在治疗肝炎病毒感染中的用途
AU2003216664A1 (en) * 2002-03-13 2003-09-22 Aarnoud C. Van Der Spoel A non-hormonal approach to male contraception
JP4585851B2 (ja) * 2002-07-17 2010-11-24 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
ES2572148T3 (es) 2005-05-17 2016-05-30 Amicus Therapeutics Inc Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados

Also Published As

Publication number Publication date
US20070275998A1 (en) 2007-11-29
HK1214261A1 (zh) 2016-07-22
CA2652958A1 (en) 2007-12-06
JP2009538336A (ja) 2009-11-05
ES2537572T3 (es) 2015-06-09
EP2023927A2 (en) 2009-02-18
JP5241709B2 (ja) 2013-07-17
CN101489554A (zh) 2009-07-22
WO2007140184A2 (en) 2007-12-06
EP2023927B1 (en) 2015-02-25
WO2007140184A3 (en) 2008-11-27
CN104876855A (zh) 2015-09-02
EP2023927A4 (en) 2013-04-10
US8975280B2 (en) 2015-03-10
JP2013129662A (ja) 2013-07-04

Similar Documents

Publication Publication Date Title
CA2652958C (en) Deoxynojirimycin and d-arabinitol analogs and methods of using
RU2556216C2 (ru) Производное индола и его фармацевтическое применение
CA2263167C (en) Ether muscarinic antagonists
WO2010049678A2 (en) Treatment of energy utilization diseases
NO322562B1 (no) Mutilinderivater, deres anvendelse for fremstilling av farmasoytiske midler og de derved oppnadde farmasoytiske midlene samt deres anvendelse for fremstilling av veterinaermedisinske sammensetninger.
BRPI0612599A2 (pt) composto, composição farmacêutica compreendendo o mesmo, método de tratamento e uso do mesmo
JPS6058751B2 (ja) プロリン関連化合物ならびにその製法
WO2010029313A1 (en) Antiinfective compounds
EP0749423B1 (en) Piperidines and pyrrolidines
López et al. Glycosidase inhibitors: versatile tools in glycobiology
Kato et al. Isolation and SAR studies of bicyclic iminosugars from Castanospermum australe as glycosidase inhibitors
US6020344A (en) Enzyme inhibitors and methods of use
Long et al. N-Heteroarylmethyl-5-hydroxy-1, 2, 5, 6-tetrahydropyridine-3-carboxylic acid a novel scaffold for the design of uncompetitive α-glucosidase inhibitors
SE503436C3 (sv) Pyroglutamidderivat
Kooij et al. Glycosidase inhibition by novel guanidinium and urea iminosugar derivatives
US20050049312A1 (en) Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities,and process for preparing them
Liang et al. Design, synthesis, biologically evaluation and molecular docking of C-glycosidic oximino carbamates as novel OfHex1 inhibitors
Fröhlich et al. 1-Deoxy-d-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines
SK11372001A3 (sk) Piperidínové a piperazínové deriváty ako inhibítory vzniku a'beta' fibríl
US20140296288A1 (en) Imino-sugar c-glycosides, preparation and use thereof
CN107513083B (zh) 糖基萘酰亚胺类化合物的制备方法与应用
EP3009444B1 (en) Alpha-oxoacyl amino-caprolactam derivative
EP4332093A1 (en) Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof
Ashmus et al. Rational design of cell active C2-modified DGJ analogues for the inhibition of human α-galactosidase A (GALA)
WO1995000484A1 (en) N-substituted azaheterocyclic carboxylic acids and esters thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190522